A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials
Polypharmacy and comorbidity should be considered both in the design of phase I oncology trials and in planning for healthcare utilisation during these trials.
Authors
- Sheila Matharu
- Bindumalini Raobaikady
- Udai Banerji (ORCID: https://orcid.org/0000-0003-1503-3123)
- Lisa Scerri
- Céire Costelloe (ORCID: https://orcid.org/0000-0002-3475-7525)
- Lauren Barrow
- Hoda Nemat (ORCID: https://orcid.org/0000-0003-3276-3953)
- Martin Orr
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Cancer Research UK (GB)
- Public Health England (GB)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1038/s44276-025-00165-y
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Royal Marsden NHS Foundation Trust
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care